All Title Author
Keywords Abstract

PLOS ONE  2012 

Hypothalamic mTOR Signaling Mediates the Orexigenic Action of Ghrelin

DOI: 10.1371/journal.pone.0046923

Full-Text   Cite this paper   Add to My Lib


Current evidence suggests that ghrelin, a stomach derived peptide, exerts its orexigenic action through specific modulation of Sirtuin1 (SIRT1)/p53 and AMP-activated protein kinase (AMPK) pathways, which ultimately increase the expression of agouti-related protein (AgRP) and neuropeptide Y (NPY) in the arcuate nucleus of the hypothalamus (ARC). However, there is a paucity of data about the possible action of ghrelin on alternative metabolic pathways at this level. Here, we demonstrate that ghrelin elicits a marked upregulation of the hypothalamic mammalian target of rapamycin (mTOR) signaling pathway. Of note, central inhibition of mTOR signaling with rapamycin decreased ghrelin’s orexigenic action and normalized the mRNA expression of AgRP and NPY, as well as their key downstream transcription factors, namely cAMP response-element binding protein (pCREB) and forkhead box O1 (FoxO1, total and phosphorylated). Taken together, these data indicate that, in addition to previous reported mechanisms, ghrelin also promotes feeding through modulation of hypothalamic mTOR pathway.


[1]  Sun Y, Wang P, Zheng H, Smith RG (2004) Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A 101: 4679–4684.
[2]  Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409: 194–198.
[3]  Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, et al. (2003) The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37: 649–661.
[4]  Seoane LM, López M, Tovar S, Casanueva F, Se?arís R, et al. (2003) Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology 144: 544–551.
[5]  López M, Lage R, Saha AK, Pérez-Tilve D, Vázquez MJ, et al. (2008) Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab 7: 389–399.
[6]  Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, et al. (2008) The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE 3: e1797.
[7]  Lage R, Vázquez MJ, Varela L, Saha AK, Vidal-Puig A, et al. (2010) Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender. FASEB J 24: 2670–2679.
[8]  Sangiao-Alvarellos S, Vázquez MJ, Varela L, Nogueiras R, Saha AK, et al. (2009) Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology 150: 4562–4574.
[9]  Andrews ZB, Liu ZW, Walllingford N, Erion DM, Borok E, et al. (2008) UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 454: 846–851.
[10]  Velasquez DA, Martinez G, Romero A, Vazquez MJ, Boit KD, et al. (2011) The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes 60: 1177–1185.
[11]  Tschop M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407: 908–913.
[12]  Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, et al. (2006) Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 116: 1983–1993.
[13]  Sakkou M, Wiedmer P, Anlag K, Hamm A, Seuntjens E, et al. (2007) A role for brain-specific homeobox factor bsx in the control of hyperphagia and locomotory behavior. Cell Metab 5: 450–463.
[14]  Nogueiras R, López M, Lage R, Pérez-Tilve D, Pfluger P, et al. (2008) Bsx, a Novel Hypothalamic Factor linking Feeding with Locomotor Activity, is Regulated by Energy Availability. Endocrinology 149: 3009–3015.
[15]  Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471–484.
[16]  Wang X, Proud CG (2009) Nutrient control of TORC1, a cell-cycle regulator. Trends Cell Biol 19: 260–267.
[17]  Saha AK, Xu XJ, Lawson E, Deoliveira R, Brandon AE, et al. (2010) Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes 59: 2426–2434.
[18]  Roa J, Tena-Sempere M (2010) Energy balance and puberty onset: emerging role of central mTOR signaling. Trends Endocrinol Metab 21: 519–528.
[19]  Laplante M, Sabatini DM (2012) mTOR Signaling in Growth Control and Disease. Cell 149: 274–293.
[20]  Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, et al. (2006) Hypothalamic mTOR signaling regulates food intake. Science 312: 927–930.
[21]  Ropelle ER, Pauli JR, Fernandes MF, Rocco SA, Marin RM, et al. (2008) A central role for neuronal AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) in high-protein diet-induced weight loss. Diabetes 57: 594–605.
[22]  Cota D, Matter EK, Woods SC, Seeley RJ (2008) The role of hypothalamic mammalian target of rapamycin complex 1 signaling in diet-induced obesity. J Neurosci 28: 7202–7208.
[23]  Ropelle ER, Fernandes MF, Flores MB, Ueno M, Rocco S, et al. (2008) Central exercise action increases the AMPK and mTOR response to leptin. PLoS ONE 3: e3856.
[24]  Blouet C, Ono H, Schwartz GJ (2008) Mediobasal hypothalamic p70 S6 kinase 1 modulates the control of energy homeostasis. Cell Metab 8: 459–467.
[25]  Mori H, Inoki K, Munzberg H, Opland D, Faouzi M, et al. (2009) Critical role for hypothalamic mTOR activity in energy balance. Cell Metab 9: 362–374.
[26]  Reed AS, Unger EK, Olofsson LE, Piper ML, Myers MG Jr, et al. (2010) Functional role of suppressor of cytokine signaling 3 upregulation in hypothalamic leptin resistance and long-term energy homeostasis. Diabetes 59: 894–906.
[27]  Cao R, Li A, Cho HY, Lee B, Obrietan K (2010) Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock. J Neurosci 30: 6302–6314.
[28]  Varela L, Martínez-Sánchez N, Gallego R, Vázquez MJ, Roa J, et al. (2012) Hypothalamic mTOR pathway mediates thyroid hormone-induced hyperphagia in hyperthyroidism. J Pathol 227: 209–222.
[29]  Townsend KL, Suzuki R, Huang TL, Jing E, Schulz TJ, et al. (2012) Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway. FASEB J 26: 2187–2196.
[30]  López M, Seoane LM, García MC, Diéguez C, Se?arís R (2002) Neuropeptide Y, but not agouti-related peptide or melanin-concentrating hormone, is a target Peptide for orexin-a feeding actions in the rat hypothalamus. Neuroendocrinology 75: 34–44.
[31]  Seoane LM, Tovar S, Pérez D, Mallo F, López M, et al. (2004) Orexin A suppresses in vivo GH secretion. Eur J Endocrinol 150: 731–736.
[32]  López M, Lelliott CJ, Tovar S, Kimber W, Gallego R, et al. (2006) Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes 55: 1327–1336.
[33]  Lage R, Diéguez C, López M (2006) Caffeine treatment regulates neuropeptide S system expression in the rat brain. Neurosci Lett 410: 47–51.
[34]  López M, Varela L, Vázquez MJ, Rodríguez-Cuenca S, González CR, et al. (2010) Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 16: 1001–1008.
[35]  Martínez de Morentin PB, Whittle AJ, Ferno J, Nogueiras R, Diéguez C, et al. (2012) Nicotine induces negative energy balance through hypothalamic AMP-activated protein kinase. Diabetes 61: 807–817.
[36]  Roa J, García-Galiano D, Varela L, Sánchez-Garrido MA, Pineda R, et al. (2009) The mammalian target of rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system. Endocrinology 150: 5016–5026.
[37]  Whittle AJ, Carobbio S, Martíns L, Slawik M, Hondares E, et al. (2012) Bmp8b increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell 149: 871–885.
[38]  Xu G, Li Y, An W, Li S, Guan Y, et al. (2009) Gastric mammalian target of rapamycin signaling regulates ghrelin production and food intake. Endocrinology 150: 3637–3644.
[39]  Inhoff T, Stengel A, Peter L, Goebel M, Tache Y, et al. (2010) Novel insight in distribution of nesfatin-1 and phospho-mTOR in the arcuate nucleus of the hypothalamus of rats. Peptides 31: 257–262.
[40]  Villanueva EC, Munzberg H, Cota D, Leshan RL, Kopp K, et al. (2009) Complex regulation of mammalian target of rapamycin complex 1 in the basomedial hypothalamus by leptin and nutritional status. Endocrinology 150: 4541–4551.
[41]  Kirchner H, Gutierrez JA, Solenberg PJ, Pfluger PT, Czyzyk TA, et al. (2009) GOAT links dietary lipids with the endocrine control of energy balance. Nat Med 15: 741–745.
[42]  Sangiao-Alvarellos S, Varela L, Vázquez MJ, Boit KD, Saha AK, et al. (2010) Influence of ghrelin and GH deficiency on AMPK and hypothalamic lipid metabolism. J Neuroendocrinol 22: 543–556.


comments powered by Disqus